CLINICAL SCIENCE Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study

Abstract

Methods: Twenty-four antiretroviral-naive R5 HIV-1–infected participants received maraviroc 150 mg and darunavir/ritonavir (DRV/r) 800/100 mg (MVC/DRV/r) once daily. The primary outcome was virologic failure (VF) = confirmed viral load (VL) .50 copies per milliliter at week 24 in the modified intent-to-treat population. To determine viral dynamics, participant-specific firstand secondphase empirical Bayes estimates were compared with decay rates from efavirenz (EFV) plus lopinavir/ritonavir, lopinavir/ritonavir plus 2NRTIs, and EFV plus 2NRTIs. Maraviroc plasma concentrations were determined at weeks 2, 4, 12, 24, and 48.

4 Figures and Tables

Cite this paper

@inproceedings{TaiwoCLINICALSV, title={CLINICAL SCIENCE Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study}, author={Babafemi Olapoju Taiwo and Edward P. Acosta and Pharmd and † Patrick Ryscavage and Darlene Lu and Jose Castro and Oluwatoyin Falusi Adeyemi and Daniel R. Kuritzkes and Joseph J Eron} }